Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases

被引:68
作者
Yu, Ping
Lee, Youjin
Wang, Yang
Liu, Xiaojuan
Auh, Sogyong
Gajewski, Thomas F.
Schreiber, Hans
You, Zhaoyang
Kaynor, Campbell
Wang, Xinzhong
Fu, Yang-Xin
机构
[1] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
[2] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA
[3] Univ Pittsburgh, Dept Dermatol, Pittsburgh, PA 15213 USA
[4] Biogen Inc, Cambridge, MA 02142 USA
关键词
D O I
10.4049/jimmunol.179.3.1960
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Metastatic disease is the major cause of morbidity and mortality in cancer. Although surgery, chemotherapy, or radiation can often control primary tumor growth, successful eradication of disseminated metastases remains rare. We have now tested whether direct targeting tumor tissues to generate antitumor immune response before surgical excision produces sufficient CTL against micrometastases. One unsolved problem is whether such response allows coming CTL to be educated and then exit the tumor site. Another unsolved problem is whether these CTL can then patrol and effectively eliminate spontaneously metastasized tumor cells in the periphery. In this study, we have shown that adenovirus-expressing TNFSF14 [LIGHT (name derived from homologous to (L) under bar ymphotoxins, shows inducible expression, and competes with herpes simplex virus glycoprotein D for (N) under bar erpes virus entry mediator, a receptor expressed by (T) under bar lymphocytes); Ad-LIGHT] inoculated directly into primary 4T1 tumor, a highly aggressive, spontaneously metastasizing mammary carcinoma, followed by surgical removal of the primary tumor can eradicate established and disseminated metastatic tumor cells in the peripheral tissues. Furthermore, we clearly show with a fibrosarcoma model Ag104L(d) that local treatment can generate plenty of tumor-specific CTL that exit the primary tumor and infiltrate distal tumors to completely eradicate distal tumors. Therefore, targeting the primary tumor with Ad-LIGHT before surgical excision is a new strategy to elicit better immune response for the eradication of spontaneous metastases.
引用
收藏
页码:1960 / 1968
页数:9
相关论文
共 34 条
[1]  
[Anonymous], 1991, CURRENT PROTOCOLS IM
[2]  
Bai XF, 2001, CANCER RES, V61, P6860
[3]   Cutting edge: Rapid in vivo killing by memory CD8 T cells [J].
Barber, DL ;
Wherry, EJ ;
Ahmed, R .
JOURNAL OF IMMUNOLOGY, 2003, 171 (01) :27-31
[4]   PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].
Blank, C ;
Brown, I ;
Peterson, AC ;
Spiotto, M ;
Iwai, Y ;
Honjo, T ;
Gajewski, TF .
CANCER RESEARCH, 2004, 64 (03) :1140-1145
[5]   Human tumor antigens recognized by T lymphocytes [J].
Boon, T ;
vanderBruggen, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :725-729
[6]   Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics [J].
Bromley, SK ;
Thomas, SY ;
Luster, AD .
NATURE IMMUNOLOGY, 2005, 6 (09) :895-901
[7]   Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines [J].
Browning, JL ;
Miatkowski, K ;
Sizing, I ;
Griffiths, D ;
Zafari, M ;
Benjamin, CD ;
Meier, W ;
Mackay, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :867-878
[8]   Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues [J].
Debes, GF ;
Arnold, CN ;
Young, AJ ;
Krautwald, S ;
Lipp, M ;
Hay, JB ;
Butcher, EC .
NATURE IMMUNOLOGY, 2005, 6 (09) :889-894
[9]   Timeline - The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited [J].
Fidler, IJ .
NATURE REVIEWS CANCER, 2003, 3 (06) :453-458
[10]   Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth [J].
Harrop, JA ;
McDonnell, PC ;
Brigham-Burke, M ;
Lyn, SD ;
Minton, J ;
Tan, KB ;
Dede, K ;
Spampanato, J ;
Silverman, C ;
Hensley, P ;
DiPrinzio, R ;
Emery, JG ;
Deen, K ;
Eichman, C ;
Chabot-Fletcher, M ;
Truneh, A ;
Young, PR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (42) :27548-27556